Overview
- Envudeucitinib met all primary and secondary endpoints in the ONWARD1 and ONWARD2 Phase 3 trials for moderate-to-severe plaque psoriasis.
- Across the studies, 74% achieved PASI75 and 59% reached sPGA 0/1 at four months, with about 65% hitting PASI90 and more than 40% achieving PASI100 by Week 24.
- Responses emerged quickly, with clear separation from placebo on PASI90 by Week 4, and patient-reported outcomes improved on itch and quality of life.
- Treatment was generally well tolerated through 24 weeks, with mostly mild to moderate adverse events such as headache, congestion, respiratory infections and acne.
- Envudeucitinib outperformed apremilast (Otezla) on all PASI endpoints at Week 24, analysts described the profile as potentially class-leading, shares more than doubled, and Alumis plans to present full results at a medical meeting plus report Phase 2b lupus topline in Q3 2026.